ks370g and Diabetes-Mellitus--Type-2

The antihyperglycemic actions of caffeamide derivatives, especially KS370G, in normal ICR, streptozotocin-induced diabetic (T1DM) and diet-induced diabetic (T2DM) mice were investigated in this study. Oral administration of the compound decreased the plasma glucose levels in both normal and diabetic mice, and appeared to be in a dose-dependent manner in normal and diet-induced type 2 diabetic mice. It was found that KS370G could stimulate the release of insulin in both normal and T2DM mice, and a dose of 1 mg per kg KS370G could significantly attenuate the increase of plasma glucose induced by an intraperitoneal glucose challenge test in normal and diabetic mice. Similar treatment with KS370G significantly increased glycogen content in both liver and skeletal muscle. Hence, the hypoglycemic effect of KS370G in normal and diabetic mice could be attributed to the stimulation of insulin release and the increase of glucose utilization.

Topics: Animals; Blood Glucose; Caffeic Acids; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred ICR